(Reuters) – Moderna Inc said on Tuesday it has submitted for a variation to the conditional marketing authorization with the European Medicines Agency for the evaluation of its COVID-19 vaccine’s use in children in the age-group of 6-11 years.
(Reporting by Manojna Maddipatla in Bengaluru; Editing by Arun Koyyur)
